171 related articles for article (PubMed ID: 10458773)
1. Selective amino acid substitutions of a subdominant Epstein-Barr virus LMP2-derived epitope increase HLA/peptide complex stability and immunogenicity: implications for immunotherapy of Epstein-Barr virus-associated malignancies.
Micheletti F; Guerrini R; Formentin A; Canella A; Marastoni M; Bazzaro M; Tomatis R; Traniello S; Gavioli R
Eur J Immunol; 1999 Aug; 29(8):2579-89. PubMed ID: 10458773
[TBL] [Abstract][Full Text] [Related]
2. Design of dimeric peptides obtained from a subdominant Epstein-Barr virus LMP2-derived epitope.
Marastoni M; Bazzaro M; Gavioli R; Micheletti F; Traniello S; Tomatis R
Eur J Med Chem; 2000 Jun; 35(6):593-8. PubMed ID: 10906411
[TBL] [Abstract][Full Text] [Related]
3. HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2.
Lee SP; Thomas WA; Murray RJ; Khanim F; Kaur S; Young LS; Rowe M; Kurilla M; Rickinson AB
J Virol; 1993 Dec; 67(12):7428-35. PubMed ID: 7693972
[TBL] [Abstract][Full Text] [Related]
4. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
[TBL] [Abstract][Full Text] [Related]
5. [Sequence analysis of the CTL epitopes in transmembrane region of latent membrane protein 2 of Epstein-Barr virus derived from nasopharyngeal carcinoma cells].
Zhang NH; Zhang XS; Li J; Zhang RH; Gao YF; Zeng MS
Ai Zheng; 2006 May; 25(5):566-9. PubMed ID: 16687075
[TBL] [Abstract][Full Text] [Related]
6. Immediate-early transactivator Rta of Epstein-Barr virus (EBV) shows multiple epitopes recognized by EBV-specific cytotoxic T lymphocytes.
Pepperl S; Benninger-Döring G; Modrow S; Wolf H; Jilg W
J Virol; 1998 Nov; 72(11):8644-9. PubMed ID: 9765404
[TBL] [Abstract][Full Text] [Related]
7. Three immunoproteasome-associated subunits cooperatively generate a cytotoxic T-lymphocyte epitope of Epstein-Barr virus LMP2A by overcoming specific structures resistant to epitope liberation.
Ito Y; Kondo E; Demachi-Okamura A; Akatsuka Y; Tsujimura K; Tanimoto M; Morishima Y; Takahashi T; Kuzushima K
J Virol; 2006 Jan; 80(2):883-90. PubMed ID: 16378990
[TBL] [Abstract][Full Text] [Related]
8. Activation of epitope-specific memory cytotoxic T lymphocyte responses by synthetic peptides.
Reali E; Guerrini R; Giori B; Borghi M; Marastoni M; Tomatis R; Traniello S; Masucci MG; Gavioli R
Clin Exp Immunol; 1996 Aug; 105(2):369-75. PubMed ID: 8706347
[TBL] [Abstract][Full Text] [Related]
9. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies.
Gottschalk S; Edwards OL; Sili U; Huls MH; Goltsova T; Davis AR; Heslop HE; Rooney CM
Blood; 2003 Mar; 101(5):1905-12. PubMed ID: 12411306
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma.
Duraiswamy J; Sherritt M; Thomson S; Tellam J; Cooper L; Connolly G; Bharadwaj M; Khanna R
Blood; 2003 Apr; 101(8):3150-6. PubMed ID: 12468425
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.
Tischer S; Dieks D; Sukdolak C; Bunse C; Figueiredo C; Immenschuh S; Borchers S; Stripecke R; Maecker-Kolhoff B; Blasczyk R; Eiz-Vesper B
J Immunol Methods; 2014 Jun; 408():101-13. PubMed ID: 24877879
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic T lymphocyte epitope analogues containing cis- or trans-4-aminocyclohexanecarboxylic acid residues.
Marastoni M; Bazzaro M; Micheletti F; Gavioli R; Tomatis R
Bioorg Med Chem; 2002 Sep; 10(9):3061-6. PubMed ID: 12110330
[TBL] [Abstract][Full Text] [Related]
13. HLA-A11-restricted epitope polymorphism among Epstein-Barr virus strains in the highly HLA-A11-positive Chinese population: incidence and immunogenicity of variant epitope sequences.
Midgley RS; Bell AI; Yao QY; Croom-Carter D; Hislop AD; Whitney BM; Chan AT; Johnson PJ; Rickinson AB
J Virol; 2003 Nov; 77(21):11507-16. PubMed ID: 14557636
[TBL] [Abstract][Full Text] [Related]
14. Nonresponsiveness to an immunodominant Epstein-Barr virus-encoded cytotoxic T-lymphocyte epitope in nuclear antigen 3A: implications for vaccine strategies.
Schmidt C; Burrows SR; Sculley TB; Moss DJ; Misko IS
Proc Natl Acad Sci U S A; 1991 Nov; 88(21):9478-82. PubMed ID: 1719531
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic T-lymphocyte responses to a polymorphic Epstein-Barr virus epitope identify healthy carriers with coresident viral strains.
Brooks JM; Croom-Carter DS; Leese AM; Tierney RJ; Habeshaw G; Rickinson AB
J Virol; 2000 Feb; 74(4):1801-9. PubMed ID: 10644353
[TBL] [Abstract][Full Text] [Related]
16. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs.
Gottschalk S; Ng CY; Perez M; Smith CA; Sample C; Brenner MK; Heslop HE; Rooney CM
Blood; 2001 Feb; 97(4):835-43. PubMed ID: 11159505
[TBL] [Abstract][Full Text] [Related]
17. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy.
Lee SP; Tierney RJ; Thomas WA; Brooks JM; Rickinson AB
J Immunol; 1997 Apr; 158(7):3325-34. PubMed ID: 9120290
[TBL] [Abstract][Full Text] [Related]
18. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease.
Bollard CM; Straathof KC; Huls MH; Leen A; Lacuesta K; Davis A; Gottschalk S; Brenner MK; Heslop HE; Rooney CM
J Immunother; 2004; 27(4):317-27. PubMed ID: 15235393
[TBL] [Abstract][Full Text] [Related]
19. The lifespan of major histocompatibility complex class I/peptide complexes determines the efficiency of cytotoxic T-lymphocyte responses.
Micheletti F; Bazzaro M; Canella A; Marastoni M; Traniello S; Gavioli R
Immunology; 1999 Mar; 96(3):411-5. PubMed ID: 10233722
[TBL] [Abstract][Full Text] [Related]
20. Polymorphonuclear neutrophils pulsed with synthetic peptides efficiently activate memory cytotoxic T lymphocytes.
Reali E; Guerrini R; Moretti S; Spisani S; Lanza F; Tomatis R; Traniello S; Gavioli R
J Leukoc Biol; 1996 Aug; 60(2):207-13. PubMed ID: 8773582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
